IRIDEX Corporation(IRIX)Earnings, Financials & Key Ratios
IRIX•NASDAQ
$1.03
$18M mkt cap·Price updated May 7, 2026
AboutIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Show more
- Revenue$49M-6.2%
- EBITDA-$7M+13.8%
- Net Income-$9M+6.9%
- EPS (Diluted)-0.54+8.5%
- Gross Margin40.07%-4.7%
- EBITDA Margin-14.13%+8.1%
- Operating Margin-17.06%+11.6%
- Net Margin-18.31%+0.8%
- ROE-153.37%-114.4%
- ROIC-129.89%+10.8%
- Debt/Equity2.21+667.8%
IRIX Key Insights
IRIDEX Corporation (IRIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 1.7x turnover
✗Weaknesses
- ✗High debt to equity ratio of 2.2x
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IRIX Price & Volume
IRIDEX Corporation (IRIX) stock price & volume — 10-year historical chart
Loading chart...
IRIX Growth Metrics
IRIDEX Corporation (IRIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.29%
5 Years2.3%
3 Years-3.35%
TTM4.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM53.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.33%
Return on Capital
10 Years-28.39%
5 Years-33.53%
3 Years-36.9%
Last Year-48.78%
IRIX Peer Comparison
IRIDEX Corporation (IRIX) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LASE | 16.07M | 0.72 | -3.29 | -13.31% | -105.37% | -183.55% | 0.49 | |
 ARAY | 34.82M | 0.29 | -18.91 | 2.68% | -10.76% | -77.48% | 2.17 | |
 GKOS | 7.85B | 134.15 | -40.90 | 32.33% | -34.34% | -26.46% | 0.21 | |
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ALGN | 12.06B | 168.39 | 29.80 | 0.9% | 10.5% | 10.7% | 0.03 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ISRG | 161.07B | 453.49 | 57.62 | 20.51% | 28.15% | 16.89% | 0.02 | |
 SYK | 112.69B | 294.25 | 35.03 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare IRIX vs Peers
IRIDEX Corporation (IRIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRIX Income Statement
IRIDEX Corporation (IRIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 46.16M | 41.59M | 42.6M | 43.45M | 36.35M | 53.9M | 56.97M | 51.87M | 48.67M | 50.65M |
| Revenue Growth % | 10.54% | -9.89% | 2.42% | 1.99% | -16.34% | 48.3% | 5.69% | -8.96% | -6.17% | 4.58% |
| Cost of Goods Sold | 25.32M | 26.09M | 25.13M | 25.51M | 20.79M | 31.07M | 31.6M | 30.06M | 29.17M | 31.39M |
| COGS % of Revenue | 54.85% | 62.73% | 58.99% | 58.71% | 57.2% | 57.64% | 55.47% | 57.96% | 59.93% | - |
| Gross Profit | 20.84M▲ 0% | 15.5M▼ 25.6% | 17.47M▲ 12.7% | 17.94M▲ 2.7% | 15.56M▼ 13.3% | 22.83M▲ 46.7% | 25.37M▲ 11.1% | 21.81M▼ 14.0% | 19.5M▼ 10.6% | 19.26M▲ 0% |
| Gross Margin % | 45.15% | 37.27% | 41.01% | 41.29% | 42.8% | 42.36% | 44.53% | 42.04% | 40.07% | 38.02% |
| Gross Profit Growth % | 4.44% | -25.61% | 12.69% | 2.68% | -13.27% | 46.75% | 11.11% | -14.04% | -10.57% | - |
| Operating Expenses | 23.28M | 28.53M | 30.34M | 26.91M | 22.14M | 30.36M | 32.91M | 31.81M | 27.8M | 22.32M |
| OpEx % of Revenue | 50.44% | 68.6% | 71.22% | 61.94% | 60.92% | 56.33% | 57.77% | 61.34% | 57.13% | - |
| Selling, General & Admin | 17.92M | 22.8M | 26.33M | 23.23M | 18.86M | 23.5M | 25.73M | 24.98M | 22.36M | 18.56M |
| SG&A % of Revenue | 38.82% | 54.82% | 61.81% | 53.47% | 51.89% | 43.59% | 45.17% | 48.17% | 45.93% | - |
| Research & Development | 5.37M | 5.73M | 4.01M | 3.68M | 3.28M | 6.87M | 7.17M | 6.83M | 5.45M | 3.83M |
| R&D % of Revenue | 11.62% | 13.78% | 9.4% | 8.47% | 9.03% | 12.74% | 12.59% | 13.17% | 11.2% | - |
| Other Operating Expenses | -91K | -107K | 92K | 0 | 0 | 0 | 0 | 0 | 0 | -79K |
| Operating Income | -2.56M▲ 0% | -12.89M▼ 402.5% | -12.87M▲ 0.2% | -8.97M▲ 30.3% | -6.58M▲ 26.6% | -7.53M▼ 14.4% | -7.54M▼ 0.1% | -10.01M▼ 32.7% | -8.3M▲ 17.0% | -3.06M▲ 0% |
| Operating Margin % | -5.56% | -30.99% | -30.21% | -20.66% | -18.11% | -13.98% | -13.24% | -19.29% | -17.06% | -6.04% |
| Operating Income Growth % | -990.63% | -402.46% | 0.16% | 30.26% | 26.64% | -14.43% | -0.12% | -32.68% | 17.04% | - |
| EBITDA | -1.92M | -12.03M | -12.06M | -8.29M | -6.08M | -6.73M | -6.16M | -7.97M | -6.88M | -1.56M |
| EBITDA Margin % | -4.15% | -28.92% | -28.31% | -19.07% | -16.72% | -12.49% | -10.81% | -15.38% | -14.13% | -3.07% |
| EBITDA Growth % | -336.67% | -527.54% | -0.24% | 31.29% | 26.64% | -10.71% | 8.5% | -29.51% | 13.76% | 82.82% |
| D&A (Non-Cash Add-back) | 648K | 858K | 809K | 688K | 504K | 803K | 1.38M | 2.03M | 1.42M | 1.5M |
| EBIT | -2.44M | -13.03M | -12.87M | -8.97M | -6.58M | -7.53M | -7.54M | -10.01M | -8.3M | -4.72M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -91K | -107K | 92K | 209K | 280K | 2.35M | 60K | 527K | -540K | -2M |
| Pretax Income | -2.66M▲ 0% | -12.99M▼ 389.3% | -12.78M▲ 1.7% | -8.77M▲ 31.4% | -6.3M▲ 28.1% | -5.18M▲ 17.7% | -7.48M▼ 44.3% | -9.48M▼ 26.7% | -8.84M▲ 6.7% | -5.06M▲ 0% |
| Pretax Margin % | -5.75% | -31.24% | -29.99% | -20.17% | -17.34% | -9.62% | -13.13% | -18.28% | -18.17% | -9.98% |
| Income Tax | 9.06M | -128K | 37K | 48K | 26K | 40K | 65K | 90K | 68K | 31K |
| Effective Tax Rate % | -341% | 0.98% | -0.29% | -0.55% | -0.41% | -0.77% | -0.87% | -0.95% | -0.77% | -0.61% |
| Net Income | -11.71M▲ 0% | -12.87M▼ 9.9% | -12.81M▲ 0.4% | -8.81M▲ 31.2% | -6.33M▲ 28.2% | -5.22M▲ 17.4% | -7.55M▼ 44.4% | -9.57M▼ 26.8% | -8.91M▲ 6.9% | -5.09M▲ 0% |
| Net Margin % | -25.38% | -30.94% | -30.08% | -20.28% | -17.41% | -9.69% | -13.25% | -18.45% | -18.31% | -10.04% |
| Net Income Growth % | -2571.1% | -9.85% | 0.42% | 31.22% | 28.19% | 17.44% | -44.44% | -26.81% | 6.9% | 53.91% |
| Net Income (Continuing) | -11.71M | -12.87M | -12.81M | -8.81M | -6.33M | -5.22M | -7.55M | -9.57M | -8.91M | -5.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.15▲ 0% | -1.11▲ 3.5% | -1.05▲ 5.4% | -0.64▲ 39.0% | -0.46▲ 28.1% | -0.34▲ 26.1% | -0.47▼ 38.2% | -0.59▼ 25.5% | -0.54▲ 8.5% | -0.30▲ 0% |
| EPS Growth % | -2400% | 3.48% | 5.41% | 39.05% | 28.13% | 26.09% | -38.24% | -25.53% | 8.47% | 55.33% |
| EPS (Basic) | -1.15 | -1.11 | -1.05 | -0.64 | -0.46 | -0.34 | -0.47 | -0.59 | -0.54 | - |
| Diluted Shares Outstanding | 10.17M | 11.55M | 12.2M | 13.71M | 13.84M | 15.42M | 15.94M | 16.13M | 16.44M | 17.01M |
| Basic Shares Outstanding | 10.17M | 11.55M | 12.2M | 13.71M | 13.84M | 15.42M | 15.94M | 16.13M | 16.44M | 17.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IRIX Balance Sheet
IRIDEX Corporation (IRIX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 45.87M | 39.45M | 39.62M | 30.55M | 25.36M | 42.25M | 35.77M | 27.45M | 23.56M | 24.07M |
| Cash & Short-Term Investments | 23.75M | 21.71M | 21.19M | 12.65M | 11.63M | 23.85M | 13.92M | 7.03M | 2.39M | 5.57M |
| Cash Only | 23.75M | 21.71M | 21.19M | 12.65M | 11.63M | 23.85M | 13.92M | 7.03M | 2.39M | 5.57M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 10.03M | 7.86M | 9.08M | 9.32M | 7.29M | 9.72M | 9.77M | 9.65M | 8.39M | 9.53M |
| Days Sales Outstanding | 79.27 | 69 | 77.82 | 78.32 | 73.2 | 65.79 | 62.58 | 67.93 | 62.95 | 67.27 |
| Inventory | 11.64M | 9.38M | 8.79M | 8.17M | 5.71M | 7.61M | 10.61M | 9.91M | 10.82M | 7.3M |
| Days Inventory Outstanding | 167.85 | 131.24 | 127.73 | 116.96 | 100.32 | 89.44 | 122.51 | 120.27 | 135.37 | 106.67 |
| Other Current Assets | 450K | 500K | 547K | 0 | 0 | 0 | 1.47M | 856K | 1.96M | 1.66M |
| Total Non-Current Assets | 2.28M | 2.19M | 2.05M | 4.26M | 2.61M | 6.43M | 6.52M | 6.99M | 5.57M | 4.29M |
| Property, Plant & Equipment | 1.53M | 1.4M | 1.22M | 3.49M | 1.88M | 2.99M | 2.13M | 2.98M | 1.91M | 1.06M |
| Fixed Asset Turnover | 30.09x | 29.65x | 34.92x | 12.43x | 19.36x | 18.01x | 26.79x | 17.39x | 25.52x | 34.19x |
| Goodwill | 533K | 533K | 533K | 533K | 533K | 965K | 965K | 965K | 965K | 965K |
| Intangible Assets | 132K | 116K | 100K | 84K | 68K | 2.21M | 1.98M | 1.64M | 1.31M | 1.06M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 80K | 143K | 201K | 151K | 132K | 271K | 1.46M | 1.4M | 1.39M | 5.16M |
| Total Assets | 48.14M▲ 0% | 41.65M▼ 13.5% | 41.67M▲ 0.1% | 34.81M▼ 16.5% | 27.97M▼ 19.7% | 48.69M▲ 74.1% | 42.29M▼ 13.1% | 34.44M▼ 18.6% | 29.14M▼ 15.4% | 28.35M▲ 0% |
| Asset Turnover | 0.96x | 1.00x | 1.02x | 1.25x | 1.30x | 1.11x | 1.35x | 1.51x | 1.67x | 1.64x |
| Asset Growth % | 15.11% | -13.5% | 0.06% | -16.46% | -19.66% | 74.07% | -13.14% | -18.57% | -15.39% | -19.87% |
| Total Current Liabilities | 8.46M | 10.39M | 11.09M | 9.78M | 8.68M | 12.65M | 12.45M | 12.97M | 16.56M | 12.39M |
| Accounts Payable | 1.99M | 1.72M | 2.52M | 2.59M | 1.15M | 2.77M | 3.86M | 4.5M | 6.99M | 4.62M |
| Days Payables Outstanding | 28.75 | 24.12 | 36.55 | 37.09 | 20.16 | 32.56 | 44.56 | 54.62 | 87.41 | 66.77 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1.25M | 0 | 0 | 0 | 1.73M | 1.03M |
| Deferred Revenue (Current) | 1.38M | 2.52M | 2.23M | 2.23M | 938K | 3.45M | 3.38M | 3.33M | 3.49M | 10.05M |
| Other Current Liabilities | 2.64M | 3.63M | 3.23M | 2.78M | 1.97M | 3.19M | 2.45M | 1.62M | 770K | 2.6M |
| Current Ratio | 5.42x | 3.80x | 3.57x | 3.12x | 2.92x | 3.34x | 2.87x | 2.12x | 1.42x | 1.42x |
| Quick Ratio | 4.04x | 2.89x | 2.78x | 2.29x | 2.26x | 2.74x | 2.02x | 1.35x | 0.77x | 0.77x |
| Cash Conversion Cycle | 218.37 | 176.12 | 169.01 | 158.2 | 153.36 | 122.67 | 140.54 | 133.58 | 110.91 | 107.18 |
| Total Non-Current Liabilities | 523K | 732K | 623K | 2.33M | 1.92M | 12.74M | 12.61M | 11.94M | 10.48M | 11.28M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 1.25M | 0 | 0 | 0 | 1M | 3.71M |
| Capital Lease Obligations | 0 | 0 | 0 | 1.79M | 282K | 1.73M | 732K | 1.75M | 811K | 1.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 523K | 732K | 623K | 175K | 103K | 83K | 132K | 164K | 314K | 7.23M |
| Total Liabilities | 8.98M | 11.12M | 11.71M | 12.11M | 10.6M | 25.39M | 25.06M | 24.91M | 27.04M | 23.67M |
| Total Debt | 0 | 0 | 0 | 3.21M | 4.19M | 2.66M | 1.77M | 2.75M | 4.64M | 4.79M |
| Net Debt | -23.75M | -21.71M | -21.19M | -9.44M | -7.44M | -21.2M | -12.15M | -4.29M | 2.26M | -788K |
| Debt / Equity | - | - | - | 0.14x | 0.24x | 0.11x | 0.10x | 0.29x | 2.21x | 2.21x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.51x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 39.16M▲ 0% | 30.52M▼ 22.1% | 29.96M▼ 1.8% | 22.7M▼ 24.2% | 17.37M▼ 23.5% | 23.3M▲ 34.2% | 17.23M▼ 26.0% | 9.52M▼ 44.7% | 2.1M▼ 78.0% | 4.68M▲ 0% |
| Equity Growth % | 16.24% | -22.06% | -1.84% | -24.22% | -23.51% | 34.16% | -26.04% | -44.74% | -77.98% | -43.69% |
| Book Value per Share | 3.85 | 2.64 | 2.46 | 1.66 | 1.25 | 1.51 | 1.08 | 0.59 | 0.13 | 0.28 |
| Total Shareholders' Equity | 39.16M | 30.52M | 29.96M | 22.7M | 17.37M | 23.3M | 17.23M | 9.52M | 2.1M | 4.68M |
| Common Stock | 124K | 126K | 145K | 147K | 148K | 168K | 169K | 172K | 174K | 174K |
| Retained Earnings | -16.12M | -28.99M | -41.8M | -50.62M | -56.94M | -62.17M | -69.72M | -79.04M | -88.01M | -92.26M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -10.34M | -11.05M | 70K | 80K | -19K | 45K | -24K | -52K | 51K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IRIX Cash Flow Statement
IRIDEX Corporation (IRIX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -144K | -3.56M | -10.03M | -7.91M | -3.24M | 8.22M | -9.52M | -6.75M | -7.29M | -7.29M |
| Operating CF Margin % | -0.31% | -8.57% | -23.53% | -18.21% | -8.91% | 15.24% | -16.71% | -13% | -14.97% | - |
| Operating CF Growth % | 75.72% | -2375.69% | -181.21% | 21.07% | 59.09% | 353.85% | -215.85% | 29.14% | -8.01% | 173.88% |
| Net Income | -11.71M | -12.87M | -12.81M | -8.81M | -6.33M | -5.22M | -7.55M | -9.57M | -8.91M | -5.09M |
| Depreciation & Amortization | 648K | 858K | 809K | 688K | 504K | 1.71M | 1.38M | 2.03M | 1.42M | 1.5M |
| Stock-Based Compensation | 1.82M | 1.92M | 1.8M | 1.7M | 1.12M | 1.63M | 0 | 0 | 1.24M | 470K |
| Deferred Taxes | 8.98M | -140K | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 337K | 260K | 149K | 74K | 198K | -2.46M | 1.81M | 1.65M | 328K | 3.22M |
| Working Capital Changes | -222K | 6.4M | 23K | -1.56M | 1.27M | 12.56M | -5.16M | -857K | -1.37M | -2.89M |
| Change in Receivables | -865K | 2.16M | -1.16M | -271K | 1.86M | -2.47M | -237K | 358K | 1.26M | -2.25M |
| Change in Inventory | -537K | 2.09M | 463K | 545K | 2.38M | 268K | -3.02M | 644K | -911K | 2.51M |
| Change in Payables | -229K | -270K | 788K | 76K | -1.45M | 1.63M | 1.09M | 641K | 2.49M | -1.24M |
| Cash from Investing | -1.47M | -782K | -827K | -509K | -93K | -5.56M | -286K | -109K | -13K | -33K |
| Capital Expenditures | -1.06M | -575K | -440K | -128K | -97K | -213K | -286K | -109K | -13K | -33K |
| CapEx % of Revenue | 2.3% | 1.38% | 1.03% | 0.29% | 0.27% | 0.4% | 0.5% | 0.21% | 0.03% | - |
| Acquisitions | -406K | -382K | -387K | 0 | 0 | -5.34M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -406K | -207K | -387K | -381K | 4K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 15.36M | 2.31M | 10.38M | -156K | 2.47M | 9.47M | -73K | -5K | 2.6M | 5.81M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 2.5M | 0 | 0 | 0 | -218K | -179K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | 0 | 1000K | 21K | 82K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 610K | 44K | -96K | -156K | -30K | -412K | -94K | -87K | -547K | -14K |
| Net Change in Cash | 13.75M▲ 0% | -2.04M▼ 114.8% | -513K▲ 74.9% | -8.54M▼ 1564.9% | -1.03M▲ 88.0% | 12.23M▲ 1290.5% | -9.93M▼ 181.2% | -6.89M▲ 30.6% | -4.65M▲ 32.5% | 1.71M▲ 0% |
| Free Cash Flow | -1.21M▲ 0% | -4.14M▼ 243.3% | -10.46M▼ 152.8% | -8.04M▲ 23.2% | -3.33M▲ 58.5% | 8M▲ 340.1% | -9.8M▼ 222.5% | -6.85M▲ 30.1% | -7.3M▼ 6.5% | -2.82M▲ 0% |
| FCF Margin % | -2.61% | -9.95% | -24.57% | -18.51% | -9.17% | 14.85% | -17.21% | -13.21% | -15% | -5.56% |
| FCF Growth % | 17.85% | -243.28% | -152.78% | 23.16% | 58.54% | 340.07% | -222.5% | 30.1% | -6.48% | 59.75% |
| FCF per Share | -0.12 | -0.36 | -0.86 | -0.59 | -0.24 | 0.52 | -0.62 | -0.42 | -0.44 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.01x | 0.28x | 0.78x | 0.90x | 0.51x | -1.57x | 1.26x | 0.70x | 0.82x | 0.55x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 22K | 7K | 13K | 14K | 0 | 15K | 0 | 0 | 15K | 24K |
IRIX Key Ratios
IRIDEX Corporation (IRIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -32.16% | -36.93% | -42.37% | -33.47% | -31.59% | -25.7% | -37.24% | -71.54% | -153.37% | -108.67% |
| Return on Invested Capital (ROIC) | -9.84% | -79.79% | -109.78% | -61.11% | -42.58% | -93.92% | -157.54% | -145.56% | -129.89% | -129.89% |
| Gross Margin | 45.15% | 37.27% | 41.01% | 41.29% | 42.8% | 42.36% | 44.53% | 42.04% | 40.07% | 38.02% |
| Net Margin | -25.38% | -30.94% | -30.08% | -20.28% | -17.41% | -9.69% | -13.25% | -18.45% | -18.31% | -10.04% |
| Debt / Equity | - | - | - | 0.14x | 0.24x | 0.11x | 0.10x | 0.29x | 2.21x | 2.21x |
| FCF Conversion | 0.01x | 0.28x | 0.78x | 0.90x | 0.51x | -1.57x | 1.26x | 0.70x | 0.82x | 0.55x |
| Revenue Growth | 10.54% | -9.89% | 2.42% | 1.99% | -16.34% | 48.3% | 5.69% | -8.96% | -6.17% | 4.58% |
IRIX Frequently Asked Questions
IRIDEX Corporation (IRIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IRIDEX Corporation (IRIX) reported $50.6M in revenue for fiscal year 2024. This represents a 476% increase from $8.8M in 1995.
IRIDEX Corporation (IRIX) saw revenue decline by 6.2% over the past year.
IRIDEX Corporation (IRIX) reported a net loss of $5.1M for fiscal year 2024.
Dividend & Returns
IRIDEX Corporation (IRIX) has a return on equity (ROE) of -153.4%. Negative ROE indicates the company is unprofitable.
IRIDEX Corporation (IRIX) had negative free cash flow of $2.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More IRIX
IRIDEX Corporation (IRIX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates